Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Aarti Drugs Limited is a leading player in the specialty and generic pharmaceuticals sector, primarily focusing on APIs (Active Pharmaceutical Ingredients) and formulations. The company operates in India and exports to over 100 countries, leveraging its strong R&D capabilities and regulatory compliance to maintain a competitive edge in a rapidly evolving market.
Aarti Drugs generates revenue through the production and sale of APIs and finished pharmaceutical formulations, benefiting from economies of scale and a diversified product portfolio. Its strong R&D capabilities allow for innovation and adaptation to market needs, while its established relationships with global clients enhance pricing power.
Regulatory approvals for new drug formulations
Changes in API pricing dynamics due to global supply chain shifts
Market expansion in emerging economies, particularly in Africa and Southeast Asia
New partnerships or contracts with major pharmaceutical companies
Regulatory changes in key markets that could affect product approvals
Technological disruption in drug manufacturing processes
Intensifying competition from both domestic and international generic drug manufacturers
Potential price erosion in the API market due to oversupply
Moderate liquidity risk due to significant capital expenditures (Capex of $1.7B)
Potential foreign exchange risk from international sales
moderate - As a pharmaceutical manufacturer, Aarti Drugs is somewhat insulated from economic downturns, but demand for non-essential medications may decline during recessions.
Low - The company has a low debt-to-equity ratio (0.37), which minimizes sensitivity to interest rate fluctuations. However, higher rates could impact consumer spending on healthcare products.
minimal - Aarti Drugs operates with a strong balance sheet and low reliance on external financing.
growth - Investors are likely attracted to Aarti Drugs for its strong revenue and net income growth rates, as well as its potential for expansion in emerging markets.
moderate - The stock has shown volatility, with a 1-year return of -21.5%, indicating sensitivity to market conditions and investor sentiment.
